A phase 2 study of Pelareorep in combination with pembrolizumab (KEYTRUDA®) in patients with relapsed metastatic adenocarcinoma of the pancreas.

Next Previous
Trial Profile

A phase 2 study of Pelareorep in combination with pembrolizumab (KEYTRUDA®) in patients with relapsed metastatic adenocarcinoma of the pancreas.

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Pelareorep (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Merck & Co

    • Most Recent Events

    • 14 Mar 2018 New trial record
    • 09 Mar 2018 According to an Oncolytics Biotech media release, this study is expected to start in 2Q 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top